MicroRNAs in Bone and Soft Tissue Sarcomas and Their Value as Biomarkers

Tomohiro Fujiwara, Yu Fujita, Yutaka Nezu, Akira Kawai, Toshihumi Ozaki, Takahiro Ochiya

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Bone and soft tissue sarcomas are malignant neoplasms that are histologically and genetically heterogeneous, and various subtypes of them have been identified. Evidence of microRNA (miRNA) dysregulation in bone and soft tissue sarcomas has been recently described. miRNA dysregulation that is associated with genetic abnormalities unique to the specific subtypes of sarcomas, functionally important, or correlated with clinical prognosis has been gradually identified. Furthermore, the discovery of circulating miRNAs in patient blood has accelerated interest in their potential to transform clinical applications. Considering the lack of useful bone and soft tissue sarcoma biomarkers, the discovery of miRNA dysregulation may provide a diagnostic method that can be used at early disease stages to detect tumors, predict tumor response to chemotherapy, or identify prognoses. Such interventions would address some of the most important challenges in sarcoma management. In this review, we summarize the emerging evidence of miRNA dysregulation in bone and soft tissue sarcomas and discuss their potential as novel biomarkers and therapeutics.

Original languageEnglish
Title of host publicationEpigenetic Biomarkers and Diagnostics
PublisherElsevier Inc.
Pages613-642
Number of pages30
ISBN (Electronic)9780128019214
ISBN (Print)9780128018996
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Biomarkers
MicroRNAs
Sarcoma
Bone
Tissue
Bone and Bones
Tumors
Chemotherapy
Neoplasms
Blood
Drug Therapy

Keywords

  • Biomarker
  • Bone tumor
  • MicroRNA
  • Sarcoma
  • Soft tissue tumor

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Fujiwara, T., Fujita, Y., Nezu, Y., Kawai, A., Ozaki, T., & Ochiya, T. (2015). MicroRNAs in Bone and Soft Tissue Sarcomas and Their Value as Biomarkers. In Epigenetic Biomarkers and Diagnostics (pp. 613-642). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-801899-6.00030-9

MicroRNAs in Bone and Soft Tissue Sarcomas and Their Value as Biomarkers. / Fujiwara, Tomohiro; Fujita, Yu; Nezu, Yutaka; Kawai, Akira; Ozaki, Toshihumi; Ochiya, Takahiro.

Epigenetic Biomarkers and Diagnostics. Elsevier Inc., 2015. p. 613-642.

Research output: Chapter in Book/Report/Conference proceedingChapter

Fujiwara, T, Fujita, Y, Nezu, Y, Kawai, A, Ozaki, T & Ochiya, T 2015, MicroRNAs in Bone and Soft Tissue Sarcomas and Their Value as Biomarkers. in Epigenetic Biomarkers and Diagnostics. Elsevier Inc., pp. 613-642. https://doi.org/10.1016/B978-0-12-801899-6.00030-9
Fujiwara T, Fujita Y, Nezu Y, Kawai A, Ozaki T, Ochiya T. MicroRNAs in Bone and Soft Tissue Sarcomas and Their Value as Biomarkers. In Epigenetic Biomarkers and Diagnostics. Elsevier Inc. 2015. p. 613-642 https://doi.org/10.1016/B978-0-12-801899-6.00030-9
Fujiwara, Tomohiro ; Fujita, Yu ; Nezu, Yutaka ; Kawai, Akira ; Ozaki, Toshihumi ; Ochiya, Takahiro. / MicroRNAs in Bone and Soft Tissue Sarcomas and Their Value as Biomarkers. Epigenetic Biomarkers and Diagnostics. Elsevier Inc., 2015. pp. 613-642
@inbook{fc8bda04042148c58d64ac58e7fa8110,
title = "MicroRNAs in Bone and Soft Tissue Sarcomas and Their Value as Biomarkers",
abstract = "Bone and soft tissue sarcomas are malignant neoplasms that are histologically and genetically heterogeneous, and various subtypes of them have been identified. Evidence of microRNA (miRNA) dysregulation in bone and soft tissue sarcomas has been recently described. miRNA dysregulation that is associated with genetic abnormalities unique to the specific subtypes of sarcomas, functionally important, or correlated with clinical prognosis has been gradually identified. Furthermore, the discovery of circulating miRNAs in patient blood has accelerated interest in their potential to transform clinical applications. Considering the lack of useful bone and soft tissue sarcoma biomarkers, the discovery of miRNA dysregulation may provide a diagnostic method that can be used at early disease stages to detect tumors, predict tumor response to chemotherapy, or identify prognoses. Such interventions would address some of the most important challenges in sarcoma management. In this review, we summarize the emerging evidence of miRNA dysregulation in bone and soft tissue sarcomas and discuss their potential as novel biomarkers and therapeutics.",
keywords = "Biomarker, Bone tumor, MicroRNA, Sarcoma, Soft tissue tumor",
author = "Tomohiro Fujiwara and Yu Fujita and Yutaka Nezu and Akira Kawai and Toshihumi Ozaki and Takahiro Ochiya",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/B978-0-12-801899-6.00030-9",
language = "English",
isbn = "9780128018996",
pages = "613--642",
booktitle = "Epigenetic Biomarkers and Diagnostics",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - MicroRNAs in Bone and Soft Tissue Sarcomas and Their Value as Biomarkers

AU - Fujiwara, Tomohiro

AU - Fujita, Yu

AU - Nezu, Yutaka

AU - Kawai, Akira

AU - Ozaki, Toshihumi

AU - Ochiya, Takahiro

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Bone and soft tissue sarcomas are malignant neoplasms that are histologically and genetically heterogeneous, and various subtypes of them have been identified. Evidence of microRNA (miRNA) dysregulation in bone and soft tissue sarcomas has been recently described. miRNA dysregulation that is associated with genetic abnormalities unique to the specific subtypes of sarcomas, functionally important, or correlated with clinical prognosis has been gradually identified. Furthermore, the discovery of circulating miRNAs in patient blood has accelerated interest in their potential to transform clinical applications. Considering the lack of useful bone and soft tissue sarcoma biomarkers, the discovery of miRNA dysregulation may provide a diagnostic method that can be used at early disease stages to detect tumors, predict tumor response to chemotherapy, or identify prognoses. Such interventions would address some of the most important challenges in sarcoma management. In this review, we summarize the emerging evidence of miRNA dysregulation in bone and soft tissue sarcomas and discuss their potential as novel biomarkers and therapeutics.

AB - Bone and soft tissue sarcomas are malignant neoplasms that are histologically and genetically heterogeneous, and various subtypes of them have been identified. Evidence of microRNA (miRNA) dysregulation in bone and soft tissue sarcomas has been recently described. miRNA dysregulation that is associated with genetic abnormalities unique to the specific subtypes of sarcomas, functionally important, or correlated with clinical prognosis has been gradually identified. Furthermore, the discovery of circulating miRNAs in patient blood has accelerated interest in their potential to transform clinical applications. Considering the lack of useful bone and soft tissue sarcoma biomarkers, the discovery of miRNA dysregulation may provide a diagnostic method that can be used at early disease stages to detect tumors, predict tumor response to chemotherapy, or identify prognoses. Such interventions would address some of the most important challenges in sarcoma management. In this review, we summarize the emerging evidence of miRNA dysregulation in bone and soft tissue sarcomas and discuss their potential as novel biomarkers and therapeutics.

KW - Biomarker

KW - Bone tumor

KW - MicroRNA

KW - Sarcoma

KW - Soft tissue tumor

UR - http://www.scopus.com/inward/record.url?scp=85018853265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018853265&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-801899-6.00030-9

DO - 10.1016/B978-0-12-801899-6.00030-9

M3 - Chapter

AN - SCOPUS:85018853265

SN - 9780128018996

SP - 613

EP - 642

BT - Epigenetic Biomarkers and Diagnostics

PB - Elsevier Inc.

ER -